G-CSF receptor truncations found in SCN/AML relieve SOCS3-controlled inhibition of STAT5 but leave suppression of STAT3 intact by Gits, J. (Judith) et al.
HEMATOPOIESIS
G-CSF receptor truncations found in SCN/AML relieve SOCS3-controlled
inhibition of STAT5 but leave suppression of STAT3 intact
Gert-Jan M. van de Geijn, Judith Gits, Lambertus H. J. Aarts, Claudia Heijmans-Antonissen, and Ivo P. Touw
Truncated granulocyte colony-stimulating
factor receptors (G-CSF-Rs) are impli-
cated in severe congenital neutropenia
(SCN) and the consecutive development
of acute myeloid leukemia (AML). Mice
expressing G-CSF-R truncation mutants
(gcsfr-d715) show defective receptor inter-
nalization, an increased signal trans-
ducer and activator of transcription 5
(STAT5)/STAT3 activation ratio, and hyper-
proliferative responses to G-CSF treat-
ment. We determined whether a lack of
negative feedback by suppressor of cyto-
kine signaling (SOCS) proteins contrib-
utes to the signaling abnormalities of
G-CSF-R–d715. Expression of SOCS3
transcripts in bone marrow cells from
G-CSF–treated gcsfr-d715 mice was ap-
proximately 60% lower than in wild-type
(WT) littermates. SOCS3 efficiently sup-
pressed STAT3 and STAT5 activation by
WT G-CSF-R in luciferase reporter as-
says. In contrast, while SOCS3 still inhib-
ited STAT3 activation by G-CSF-R–d715,
STAT5 activation was no longer affected.
This was due mainly to loss of the SOCS3
recruitment site Tyr729, with an addi-
tional contribution of the internalization
defects of G-CSF-R–d715. Because Tyr729
is also a docking site for the Src homol-
ogy 2–containing protein tyrosine phos-
phatase-2 (SHP-2), which binds to and
inactivates STAT5, we suggest a model in
which reduced SOCS3 expression, com-
bined with the loss of recruitment of both
SOCS3 and SHP-2 to the activated recep-
tor complex, determine the increased
STAT5/STAT3 activation ratio and the re-
sulting signaling abnormalities projected
by truncated G-CSF-R mutants. (Blood.
2004;104:667-674)
© 2004 by The American Society of Hematology
Introduction
Granulocyte colony-stimulating factor (G-CSF) receptor is the
major regulator of neutrophil production, both under steady-state
conditions and during stages of bacterial infections.1-3 G-CSF
exerts its activity via a receptor (G-CSF-R) of the hematopoietin
receptor superfamily.4,5 Typical of this class of receptors, G-CSF-R
has no intrinsic kinase activity but recruits cytoplasmic tyrosine
kinases of both the Janus kinase (Jak) and Src kinase families and
activates signal transducer and activator of transcription (STAT)
proteins.6-11 G-CSF activates STATs 1, 3, and 5.12-14 Whereas the
contribution of STAT1 to G-CSF responses remains unclear,
STAT3 has been implicated in G-CSF–mediated growth arrest
preceding differentiation, while activation of STAT5 has been
linked to proliferation and survival signaling.15-17 Four tyrosine
residues (Tyr704, Tyr729, Tyr744, and Tyr764) in the G-CSF-R
carboxy-terminus are involved in the recruitment of signaling
molecules, such as the adapter molecules growth factor receptor–
bound protein 2 (Grb2) and Src homology and collagen protein
(Shc) of the p21Ras–mitogen-activated protein (MAP) kinase
pathway, and the Src homology 2–containing protein tyrosine
phosphatase-2 (SHP-2).18-20 In addition, activation of STAT3
depends on its recruitment to the G-CSF-R via tyrosines 704 or
744.20-22 At higher G-CSF concentrations, STAT3 can also be
activated in a tyrosine-independent way via the G-CSF-R C-
terminus.22,23 In contrast, activation of STAT1 and STAT5 is
achieved via the membrane-proximal region of G-CSF-R and does
not require receptor tyrosine residues.13,17
In approximately 20% of patients suffering from severe congeni-
tal neutropenia (SCN), G-CSF-R mutations are found that result in
the expression of a G-CSF-R with a truncated C-terminus.24,25
These patients have an increased risk of developing acute myeloid
leukemia (AML).25,26 Activation of a G-CSF-R mutant truncated at
amino acid 715 (G-CSF-R–d715) causes a hyperproliferative
response in 32D cells, without induction of neutrophilic differentia-
tion.27 Mice with a targeted G-CSF-R–d715 mutation show various
degrees of neutropenia, and their myeloid precursors react to
G-CSF administration with hyperproliferation, resulting in a sus-
tained neutrophilia.28,29 Interestingly, transgenic (Tg) mice overex-
pressing G-CSF-R mutants truncated at amino acids (aa’s) 718 and
731 demonstrated increased susceptibility to infection with Staphy-
lococcus aureus, suggesting that production of functional neutro-
phils is compromised in these animals.30 Indeed, these Tg mice had
only one third of the peripheral neutrophil levels of wild-type (WT)
controls, and their bone marrow showed increased percentages of
immature myeloid cells.
Functional analysis of truncated receptors revealed that a
number of properties are altered compared with WT G-CSF-R.
Ligand-induced internalization of G-CSF-R–d715 is severely af-
fected owing to the loss of 2 distinct motifs in the receptor
C-terminus that are important for internalization.27,31,32 G-CSF-R–
d715 also has a somewhat reduced ability to activate STAT3,
possibly owing to the loss of the STAT3 recruitment site Tyr744
and the receptor C-terminus.22,31 In contrast, activation of STAT5 is
From the Institute of Hematology, Erasmus Medical Center, Rotterdam, The
Netherlands.
Submitted August 22, 2003; accepted March 22, 2004. Prepublished online as
Blood First Edition Paper, April 6, 2004; DOI 10.1182/blood-2003-08-2913.
Supported by the Dutch Cancer Society “Koningin Wilhelmina Fonds.”
Reprints: Ivo P. Touw, Erasmus MC, Institute of Hematology, Rm Ee 1330c,
PO Box 1738, 3000 DR Rotterdam, The Netherlands; e-mail: i.touw@
erasmusmc.nl.
The publication costs of this article were defrayed in part by page charge
payment. Therefore, and solely to indicate this fact, this article is hereby
marked ‘‘advertisement’’ in accordance with 18 U.S.C. section 1734.
© 2004 by The American Society of Hematology
667BLOOD, 1 AUGUST 2004  VOLUME 104, NUMBER 3
strongly increased and is sustained after removal of G-CSF,
suggesting a prominent role for the C-terminus in mediating
negative feedback on STAT5 activation.17,27,31 Although the defec-
tive internalization properties of truncated G-CSF-R forms contrib-
uted significantly to their sustained signaling function, it was also
clear that this did not fully explain these findings.27,32 In particular,
the differential effects of receptor truncations on the kinetics of
STAT3 versus STAT5 activation remained unclear.
Suppressor of cytokine signaling (SOCS) proteins are involved
in the down-regulation of signaling from a number of hematopoi-
etic growth factor receptors, including G-CSF-R.33-36 A conserved
SH2 domain and a C-terminal SOCS box are characteristic for the
SOCS family (reviewed in Krebs and Hilton,37 Kile and Alex-
ander,38 and Alexander39). The expression of most SOCS genes is
controlled by STAT transcription factors.40-45 SOCS proteins there-
fore act in a classical negative feedback loop to suppress cytokine
signaling. Three distinct inhibitory mechanisms have been linked
to SOCS proteins. Cytokine-inducible SH2-containing protein
(CIS), founding member of the family, inhibits activation of STAT5
by competing for STAT5 recruitment to phosphotyrosine motifs in,
for example, the growth hormone receptor (GHR) and the erythro-
poietin receptor (EpoR).46,47 SOCS1 and SOCS3, on the other
hand, directly suppress Jak kinase activity by means of a kinase
inhibitory region (KIR).48-50 Upon recruitment to the signaling
complex via the SH2 domain of SOCS, the KIR mediates inhibition
by blocking access of both adenosine triphosphate (ATP) and
substrate to their binding sites in the catalytic groove of Jak2.49-53
Finally, SOCS proteins are also thought to down-regulate signaling
via SOCS box–mediated targeting of signaling proteins for protea-
somal degradation.54,55 An important difference between SOCS1
and SOCS3 relates to how they are recruited into activated receptor
complexes. Whereas the SH2 domain of SOCS1 has a high affinity
for, for example, phosphorylated Tyr1007 in the Jak homology 1
(JH1) domain of Jak2, the affinity of the SH2 domain of SOCS3 for
this residue is much lower.49,52,56 Instead, SOCS3 is recruited with
high affinity to phosphotyrosine-based motifs in certain receptors
and then subsequently inhibits Jak activity via its KIR.34,35,48,57-59
Importantly, for a number of cytokine receptors, it has been
established that the protein tyrosine phosphatase SHP-2 and
SOCS3 dock to identical tyrosine-based motifs with comparable
affinities.57-60
Studies in SOCS-deficient mice have demonstrated major
physiologic roles for SOCS proteins in controlling the levels of
cytokine signaling in both nonhematopoietic and hematopoietic
cells.61-72 G-CSF induces the expression of SOCS1, SOCS2,
SOCS3, and CIS in hematopoietic cells,35,73 but only SOCS1 and
SOCS3 appeared to inhibit G-CSF–induced STAT activation.74 In 2
independent studies, Tyr729 of G-CSF-R was identified as the
major recruitment site for SOCS3.35,36 Recently, it was reported
that SOCS3 is a key negative regulator of G-CSF–induced
neutrophil production in vivo.75,76
In the present study, we investigated to what extent and by
which mechanism(s) truncation of the G-CSF-R C-terminus, as
found in SCN, affects the negative feedback regulation of G-CSF
signaling by SOCS3. We show that truncation of the G-CSF-R
completely relieved the inhibitory effects of SOCS3 on activation
of STAT5. In striking contrast, the suppressive effects of SOCS3 on
G-CSF-R–d715–induced activation of STAT3 were hardly affected
by the truncation. These findings provide a new mechanistic
explanation for the increased ratio of STAT5/STAT3 activation in
gcsfr-d715 mice, which has previously been linked to the shift in
the proliferation/differentiation balance in the myeloid progenitor
cell compartment found in these animals.31
Materials and methods
Expression constructs
The constructs of human G-CSF-R WT, d715, Tyr729Phe, d735, d749-769,
d715-735, and the green fluorescent protein (GFP)–G-CSF-R fusions in the
pBabe vector77 have been described before18,20,32,36 (Figure 1A). The
d735Phe and d749-769Phe mutants were generated from mutant Tyr729Phe
by, respectively, introduction of a stop codon or deletion of aa’s 749-769
with a site-directed mutagenesis kit according to the manufacturer’s
instructions (Stratagene, La Jolla, CA). Expression constructs of myc-
tagged SOCS1 and SOCS3 in pcDNA3 were a gift from A. Yoshimura.56
For expression of SHP-2, hemagglutinin (HA)–tagged human SHP-2 was
cloned into the EcoRI-XhoI sites of expression vector pSG5.78 For
expression of STAT5, pME18S-STAT5B was used.79
Bone marrow cells and isolation of RNA
WT and gcsfr-d715 mice28 were stimulated daily for 4 days with G-CSF or
received solvent only. Each experimental group contains 2 mice of each
genotype. Bone marrow cells were isolated, resuspended in TRIzol RNA
extraction reagent (Invitrogen, Breda, The Netherlands), snap frozen, and
stored at 80°C.28 For the in vitro stimulation, bone marrow cells were
harvested from 2 WT and 2 gcsfr-d715 mice that had not been treated with
G-CSF. Cells were cultured for 1 hour in Hanks balanced salt solution
(HBSS; Invitrogen) with 5% fetal calf serum (FCS); nonadherent cells were
taken and starved for 4 hours in RPMI (Invitrogen) plus 0.5% bovine serum
albumin (BSA). Cells were stimulated for the indicated periods with G-CSF
(100 ng/mL) and resuspended in Trizol. RNA was isolated according to the
manufacturer’s instructions and subsequently treated with DNAse to
remove genomic DNA. DNAse treatment of 5 g RNA was performed in
DNAse buffer (40 mM Tris-HCl [tris(hydroxymethyl)aminomethane–HCl],
Figure 1. Expression of WT and mutant G-CSF receptors. (A) Schematic
representation of the intracellular domain of the G-CSF receptor and mutants. Boxes
1 and 2 represent subdomains conserved in the hematopoietin receptor superfamily.
The open box indicates the deleted region in G-CSF-R–d749-769 and G-CSF-R–d715-
735. (B) Flow cytometric analysis of the expression levels of the different G-CSF-R
forms used in luciferase reporter assays. Open histograms indicate cells stained with
biotinylated G-CSF-R antibodies and phycoerythrin-conjugated streptavidin (SA-PE);
shaded histograms, cells stained with SA-PE only; and e.v., cells transfected with
empty vector.
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pH 7.5; 6 mM MgCl2; 2 mM CaCl2) with 10 U DNAse I (Stratagene) for 1
hour at 37°C.
Quantitative reverse-transcriptase PCR (RT-PCR)
To generate cDNA, 1 g RNA was denatured at 65°C for 5 minutes
followed by 10 minutes on ice. After addition of first-strand buffer (250 mM
Tris-HCl, pH 8.3; 375 mM KCl; 15 mM MgCl2) with deoxynucleoside
triphosphates (dNTPs; 1 mM final concentration), dithiothreitol (DTT; 1
mM final concentration), 4 g random hexamers (Amersham Pharmacia,
Uppsala, Sweden), 40 U RNasin, and 200 U Superscript II reverse
transcriptase (Invitrogen), the reaction was incubated at 42°C for 2 hours.
The cDNA was diluted 1:10, 1:30, and 1:60 for SOCS1, SOCS3, and
ribonuclease inhibitor, respectively, before polymerase chain reaction
(PCR) amplification. Primers used for amplification for SOCS1 were as
follows: FTMSOCS1, 5-tggtagcacgcaaccaggtg; and RTMSOCS1, 5-
tggcgaggacgaagacgag. Primers used for SOCS3 were FTMSOCS3, 5-
tcaagaccttcagctccaa; and RTMSOCS3, 5-tcttgacgctcaacgtgaag. Primers for
murine ribonuclease inhibitor were forward 5-tccagtgtgagcagctgag, and
reverse 5-tgcaggcactgaagcacca. For the quantitative real-time PCR, Taq-
man technology was used (Model 7900 sequence detector; PE Applied
Biosystems, Foster City, CA). The reactions were performed in a 25 L vol
of a mixture containing 2 L of the respective cDNA dilution, primers at 5
M, and 12.5 L of 2  SYBR green PCR Master mix (PE Applied
Biosystems) containing Amplitaq Gold DNA polymerase, reaction buffer,
dNTP mix with uridine 5-triphosphate (UTP), and the double-stranded
DNA–specific fluorescence dye SYBR green I. The PCR program used was
1 cycle of 2 minutes at 50°C, 1 cycle of 10 minutes at 95°C, 45 cycles of
denaturation for 15 seconds at 95°C, annealing for 30 seconds at 62°C, and
extension for 30 seconds at 62°C. To determine the expression levels,
samples were tested in duplicate, and the average values of the threshold
cycle (Ct) were used for quantification. To quantify the relative expression
of SOCS1 and SOCS3, the Ct values were normalized for endogenous
reference (Ct  CtSOCS  Ctribonuclease inhibitor) and compared with a
calibrator, by means of the Ct method (Ct  CtSample  CtCalibrator). As
calibrator for G-CSF stimulation in vivo, we used the expression in WT
bone marrow of unstimulated mice. As calibrator for the in vitro stimula-
tion, we used expression after 4 hours of starvation.
Luciferase assays
Luciferase assays were performed as described previously.36 In short,
HEK293 cells, grown in 24-well plates, were transfected by the calcium
phosphate precipitation method with a mixture of the following plasmids.
For STAT5 luciferase experiments, we used expression vector pME18S-
STAT5, a -casein–derived STAT5 luciferase reporter plasmid, a -galacto-
sidase expression plasmid pRSVLacZ, a pBabe construct with WT or
mutant G-CSF-R (Figure 1A), and different amounts of pCDNA3 with
myc-tagged SOCS or empty pcDNA3 (Invitrogen). For the STAT3 lucif-
erase experiments pME18S STAT5 was replaced by pcDNA3 vector, and an
m67-derived STAT3 luciferase reporter was added instead of the STAT5
reporter. A volume of 100 L calcium phosphate precipitate in a total of 2
g DNA was added to each well. With the exception of SOCS3, 400 ng
DNA for each construct was added per well. Different amounts of
pcDNA3-SOCS3 were added, supplemented with empty pcDNA3 vector
up to 400 ng. After 24 hours, the cells were starved overnight in Dulbecco
minimum essential medium (DMEM) plus penicillin/streptomycin (pen/
strep) plus 0.1% BSA. The next day, the cells were stimulated with 250
ng/mL G-CSF for 6 hours, lysed, and assayed for luciferase activity with the
use of Steady-Glo reagents (Promega, Madison, WI). In parallel, the
transfection efficiency was determined by means of lacZ staining. Lucif-
erase activity levels were corrected for transfection efficiency with the use
of -galactosidase expression levels. All experiments were performed in
triplicate. Fold induction by G-CSF was calculated and set at 100% in the
absence of SOCS. For inhibitor studies, the Src inhibitor PP-2, the Jak
inhibitor WHI-P154 (Calbiochem, San Diego, CA), or dimethyl sulfoxide
(DMSO) as a solvent control was added to the cells 1 hour prior to G-CSF
stimulation. Unless stated otherwise, data were analyzed by means of
analysis of variance (ANOVA). To compare G-CSF-R expression levels,
transfected cells were stained with biotinylated mouse antihuman G-CSF-R
antibody (Pharmingen, San Diego, CA) followed by SA-PE (Caltag
Laboratories, Burlingame, CA), and analyzed by flow cytometry (FACSCali-
bur; Becton Dickinson, Sunnyvale, CA). As shown in Figure 1B, G-CSF-R
expression is detectable with increased (less than 1 log unit) expression of
the internalization-defective mutants (G-CSF-R–d715, d749-769, and d749-
769Phe). As previously reported, this difference is due mainly to decreased
spontaneous internalization of these mutants in the absence of G-CSF in
nonmyeloid cells.32
Immunoprecipitations and Western blotting
Phoenix E cells (a gift from G. Nolan, Stanford, CA) were transfected with
G-CSF-R, SHP-2, and, in the case of the SHP-2-STAT5 coimmunoprecipi-
tations, with the STAT5 expression construct as well. After 24 hours, the
medium was replaced by DMEM plus 0.1% BSA. The next day, cells were
stimulated for 10 minutes with G-CSF, washed twice with cold phosphate-
buffered saline (PBS), and lysed in lysis buffer containing 20 mM Tris-HCl,
pH 8.0; 137 mM NaCl; 10 mM EDTA (ethylenediaminetetraacetic acid),
100 mM NaF, 1% Nonidet P40 (NP40), 10% glycerol, 2 mM Na3VO4, and
1 mM Pefablock SC, 50 g/mL aprotinin, 50 g/mL leupeptin, 50 g/mL
bacitracin, and 50g/mL iodoacetamide as protease inhibitors. Immunopre-
cipitations with anti-HA antibody and protein G-sepharose beads (Sigma,
Zwijndrecht, The Netherlands) and subsequent Western blotting were
performed as described previously.7 Antibodies used were mouse anti-HA
(Santa Cruz Biotechnology, Santa Cruz, CA), rabbit anti–SHP-2 (Santa
Cruz Biotechnology), mouse anti–green fluorescent protein (Roche, Al-
mere, The Netherlands), and rabbit anti-STAT5B (Santa Cruz
Biotechnology).
Results
Reduced G-CSF–induced SOCS3 expression
in gcsfr-d715 mice
SOCS proteins are under the transcriptional control of
STATs.41,43,44,78 Because G-CSF-R–d715 shows altered activation
of STAT3 and STAT5 compared with WT G-CSF-R,27,31 we first
investigated expression of SOCS1 and 3 in WT versus gcsfr-d715
mice under steady-state conditions and after daily treatment of the
animals with G-CSF for 4 days. As shown in Figure 2A, steady-
state levels of SOCS1 in gcsfr-d715 mice and their wild-type
littermates were similar. Also after G-CSF treatment, SOCS1
transcript levels in wild-type and gcsfr-d715 mice had not changed
dramatically. A slight (2.5-fold) increase in SOCS1 mRNA levels in
gcsfr-d715 mice compared with wild-type animals was noted
(Figure 2A). In contrast, SOCS3 expression was strongly (greater
than 12-fold) induced by G-CSF in WT mice, while expression
levels in gcsfr-d715 mice reached only about 30% of these levels
both after G-CSF stimulation and in steady state (Figure 2B). In
addition, we isolated bone marrow cells from untreated WT and
d715 animals and stimulated them with G-CSF in vitro. As shown
in Figure 2C, stimulation with G-CSF gives a strong induction of
SOCS3 mRNA. Again, SOCS3 transcript levels are reduced in
G-CSF-R–d715 cells upon stimulation with G-CSF. This demon-
strates that the reduced up-regulation of SOCS3 mRNA also occurs
outside the bone marrow compartment and is due to altered
signaling in the G-CSF-R–d715 cells. These results establish that
SOCS3 is the principal SOCS protein induced by G-CSF and that
C-terminal truncation of the G-CSF-R results in a significantly
reduced ability of the receptor to induce SOCS3.
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G-CSF-R truncation relieves the suppressive effects of SOCS3
on G-CSF–induced STAT5 but not STAT3 activation
We next studied the consequences of SOCS3 expression on
G-CSF–induced activation of STAT5 and STAT3 luciferase re-
porter constructs in HEK293 cell transfectants expressing either
WT G-CSF-R or G-CSF-R–d715. G-CSF–induced STAT5 activity
by WT G-CSF-R was dose dependently inhibited by SOCS3
(Figure 3A). In contrast, STAT5 activity induced by G-CSF-R–
d715 was not affected, even at the highest SOCS3 expression
levels. This finding can be reconciled with recent reports showing
that Tyr729 in G-CSF-R is the major docking site for SOCS3, a
residue that is lacking in G-CSF-R–d715.35,36 Surprisingly, STAT3
activation by G-CSF-R–d715 remained highly sensitive to inhibi-
tion by SOCS3 (Figure 3B). These data establish that Tyr729, while
essential for down-regulation of STAT5, is dispensable for the
inhibitory effects of SOCS3 on G-CSF–induced STAT3 activation.
Differential effects of SOCS3 on G-CSF-R–d715–mediated
STAT3 and STAT5 activation are not due to distinct involvement
of upstream tyrosine kinases
G-CSF-R activates the Janus kinases Jak1, Jak2, and Tyk2, but also
the Src kinases Lyn and Hck.6-8,10,11 Both the Jak and Src kinases
can phosphorylate STAT proteins in hematopoietic cells.81,82 Impor-
tantly, SOCS proteins differentially affect these kinases: in contrast
to Jak kinases, the Src kinase Lyn is insensitive to SOCS-mediated
inhibition.83 We considered a possible scenario in which Jak and
Src kinases are differentially involved in the activation of STAT3
and STAT5. In that hypothetical context, G-CSF–induced STAT5
activation by G-CSF-R–d715 would become insensitive to SOCS
because, as a result of the truncation of the receptor C-terminus,
involvement of Src activity in the activation of STAT5 might
become prevalent. To investigate this possibility, we performed the
STAT reporter experiments in the presence of the Jak inhibitor
WHI-P154 or the Src inhibitor PP-2.84,85 Both STAT3- and
STAT5-induced luciferase activity was inhibited by WHI-P154, but
not by PP-2, indicating that Jak, but not Src-kinase activity is
essential for G-CSF–induced activation of both STAT3 and STAT5
by WT G-CSF-R (Figure 4). Notably, this remained essentially
unchanged when activation was induced via G-CSF-R–d715.
Although PP-2 slightly reduced STAT5 activation, G-CSF-R–d715
signaling was still completely dependent on Jak activity. These
results thus exclude the possibility that, in the case of G-CSF-R–
d715, the loss of SOCS-mediated inhibition of STAT5 signaling is
caused by altered involvement of tyrosine kinases (eg, Lyn instead
of Jak) as a consequence of the receptor truncation. We have
previously published data from electrophoretic mobility shift
assays (EMSAs) showing that activation of STAT3 by G-CSF-R–
d715 is decreased compared with WT G-CSF-R when measured
between 0 and 60 minutes after stimulation. This is due to the
partial lack of STAT3 recruitment mechanisms.31 We observed that
activation of STAT3 by G-CSF-R–d715 in the luciferase reporter
assay was increased relative to WT G-CSF-R (Figure 4B). This
could be directly linked to the defective receptor internalization of
G-CSF-R–d715 (data not shown). Apparently, the internalization
defect of G-CSF-R–d715 causes reduced off-switch of signaling,
which results in increased accumulation of luciferase activity
during the 6-hour time period of the experiment. However, despite
Figure 2. Reduced SOCS3 but not SOCS1 expression in gcsfr-d715 mice. WT mice and gcsfr-d715 littermates were injected with vehicle or G-CSF for 4 consecutive days.
(A-B) RNA was isolated, and SOCS1 (A) and SOCS3 (B) transcript levels were measured by quantitative RT-PCR. Expression of ribonuclease inhibitor was used for
normalization of the data. SOCS levels were expressed relative to untreated WT mice. Data shown are mean standard error of the mean (SEM) of 3 experiments. *Difference
between WT and G-CSF-R–d715 is significant; P 	 .05 by Student t test. (C) SOCS3 expression in bone marrow cells deprived of growth factor for 4 hours and then stimulated
with G-CSF in vitro for the indicated times. SOCS3 levels were expressed relative to growth factor–deprived cells. Data shown are mean SEM of 4 experiments; differences
between WT and G-CSF-R–d715 are significant (Student t test, P 	 .05).
Figure 3. STAT5 activation by G-CSF-R–d715 is insensitive to inhibition by
SOCS3, whereas STAT3 activation is not. HEK293 cells transfected with STAT5 or
STAT3 luciferase reporter constructs were stimulated with G-CSF for 6 hours and
assayed for luciferase activity. G-CSF–induced STAT5 (A) or STAT3 (B) luciferase
reporter activity in the absence of SOCS3 was set at 100%. Data are expressed as
mean  95% confidence interval of 4 independent experiments. *Differences
between WT and G-CSF-R–d715 are significant; P 	 .01.
Figure 4. Effects of Jak and Src inhibitors on STAT5 and STAT3 activation by
WT G-CSF-R and G-CSF-R–d715. Luciferase assays were performed as in Figure 3.
One hour before initiation of STAT5 (A) and STAT3 (B) luciferase reporter assays, the
Src inhibitor PP-2 or the Jak inhibitor WHI-P154, dissolved in DMSO, was added to
the cells at the concentrations indicated. Solvent control cells were treated with
DMSO only. Data are expressed as mean  SEM of 3 independent experiments.
*Difference with DMSO-treated control of same group is significant; P 	 .05.
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this increased STAT3 activation, this signal remains fully sensitive
for inhibition by SOCS3 (Figure 3B,4B).
Defective G-CSF-R internalization reduces sensitivity to SOCS3
only when combined with the loss of Tyr729
G-CSF-R–d715–induced STAT5 activation was considerably more
resistant to the suppressive effects of SOCS3 than was a full-length
G-CSF-R mutant lacking the SOCS3 docking site Tyr729 (eg,
G-CSF-R–Tyr729Phe) (Figure 5). This could be suggestive of a
second, tyrosine-independent mechanism of SOCS3 recruitment
via the G-CSF-R C-terminus or relate to defective ligand-induced
internalization of G-CSF-R–d715.27,31,86 To directly address this
issue, we compared the SOCS3 sensitivity of WT G-CSF-R and
G-CSF-R–d715 with that of G-CSF-R–d749-769 (Figure 1A). This
mutant is as defective in internalization as G-CSF-R–d715, owing
to the lack of 2 internalization domains.32 As shown in Figure 5,
SOCS3 inhibits G-CSF-R–d749-769 as effectively as WT G-
CSF-R, indicating that the loss of receptor internalization per se
does not alleviate STAT5 inhibition by SOCS3. However, mutation
of SOCS3 recruitment site Tyr729 in this internalization-defective
mutant (G-CSF-R–d749-769Phe) resulted in a complete loss of
SOCS3-mediated STAT5 inhibition. These results provide evi-
dence for 2 distinct mechanisms of SOCS3 recruitment to the
G-CSF-R, one that is independent of internalization (via Tyr729)
and one that requires internalization. Possibly this latter mechanism
involves direct interaction of SOCS3 to Jaks. Both of these
mechanisms are disrupted in G-CSF-R–d715 (Figure 5).
Tyr729 is a combined recruitment site for SOCS3 and SHP-2
For a number of receptors, it has been demonstrated that SOCS3
recruitment sites are also SHP-2 docking sites.57-60 By combined
immunoprecipitation (IP) and Western-blotting (WB), we tested
whether SHP-2 binds to Tyr729 of G-CSF-R. We performed these
experiments with GFP-tagged receptor constructs and used anti-
GFP antibodies for immune detection. The GFP-tagged receptors
were shown to behave identically to the untagged receptors with
respect to proliferation, differentiation, and activation of STAT3
and STAT5.32 Stimulation with G-CSF induced coimmunoprecipi-
tation of SHP-2 with the WT G-CSF receptor (Figure 6A, lanes
1-2). Truncation of the receptor at aa 715 resulted in a complete
loss of the interaction with SHP-2 whereas truncation at aa 735 did
not affect the SHP-2–G-CSF-R interaction (Figure 6, lanes 3-4).
This result strongly supports the notion that Tyr729, the only
tyrosine present in this region, is a binding site for SHP-2. To
determine the relative contribution of Tyr729 to SHP-2 recruitment
to full-length G-CSF-R, we also tested G-CSF-R mutant d715-735
(Figure 1) in coimmunoprecipitations. Although this mutant demon-
strated a significantly reduced SHP-2 binding compared with WT
G-CSF-R, it clearly bound more SHP-2 than did G-CSF-R–d715
(Figure 6, lane 5). Taken together, these results support the notion
that Tyr729 of G-CSF-R forms a combined SOCS3 and SHP-2
recruitment site and show that an alternative mechanism of SHP-2
binding to the C-terminal region (aa’s 737-813) of G-CSF-R exists.
The latter mechanism possibly involves recruitment of SHP-2
via Tyr764.20
Tyr729 of the G-CSF-R is required for the formation of a
SHP-2–STAT5 complex
It was recently shown that SHP-2 can interact with STAT5,
resulting in dephosphorylation and inactivation of STAT5.87,88
Given the requirement of Tyr729 for recruitment of SHP-2 to the
G-CSF-R, we investigated if the formation of a SHP-2–STAT5
complex would be dependent on the presence of Tyr729 of the
G-CSF-R as well. As shown in Figure 6B (lanes 1-4), stimulation
of the WT and G-CSF-R–d735 indeed results in coimmunoprecipi-
tation of STAT5 with SHP-2. However, in the absence of Tyr729,
formation of this complex is disrupted (lanes 5-6), demonstrating
the importance of Tyr729 of the G-CSF-R for the formation of a
SHP-2–STAT5 complex.
Discussion
We investigated whether, and by which mechanism(s), altered
susceptibility to the inhibitory effects of SOCS proteins contributes
to the hyperproliferative signaling of G-CSF-R C-terminal trunca-
tion mutants, which are frequently found in SCN patients with
Figure 5. Reduced internalization of truncated G-CSF-R mutants alleviates
inhibition by SOCS3 only in the absence of Tyr729. Comparison of G-CSF-R
mutants with normal (WT and Tyr729Phe) and defective (d715, d749-769, and
d749-769Phe) internalization kinetics for sensitivity to SOCS3-mediated inhibition of
STAT5 luciferase reporter activity. STAT5 luciferase reporter assay was performed as
described in Figure 3. Data are expressed as mean of at least 2 independent
experiments with triplicate measurements. *Difference between WT and d749-769
versus all other G-CSF-R mutants is significant, P 	 .01. #Difference between
Tyr729Phe and d749-769, P  0.07. 
Difference between TyrY729Phe versus d715
and d749-769Phe is significant; P 	 .02.
Figure 6. SHP-2 associates with distinct regions of G-CSF-R,
and Tyr729 is required for the formation of a SHP-2–STAT5
complex. (A) HA–SHP-2 IPs of Phoenix E cells expressing
GFP-tagged G-CSF-R mutants. Cells were starved overnight (–)
and stimulated for 10 minutes with G-CSF. As a control, expres-
sion of GFP–G-CSF-R and SHP-2 in whole cell lysate (WCL) is
shown in the lower 2 panels. (B) HA–SHP-2 IPs of Phoenix E cells
expressing different G-CSF-R mutants and STAT5 were per-
formed as described for Figure 6A. Lane 7 is an HA-IP in the
absence of HA–SHP-2, demonstrating the specificity of the IP.
LOSS OF SOCS3 CONTROL ON TRUNCATED G-CSF-R MUTANTS 671BLOOD, 1 AUGUST 2004  VOLUME 104, NUMBER 3
disease progression toward AML.24-26 We first concentrated on the
regulation of expression of SOCS1 and SOCS3, which represent
the SOCS family members with the most prominent negative
effects on G-CSF signaling.74 Both SOCS1 and SOCS3 promoters
contain STAT-binding sites,41,43,44,80 and dominant negative STAT3
blocks SOCS1 as well as SOCS3 mRNA expression, indicating that
both SOCS genes are transcriptional targets of STAT3.41 STAT1
also binds to the SOCS3 promoter,44 but STAT3 is the major STAT
protein involved in SOCS3 induction by G-CSF. This was demon-
strated most clearly in conditional STAT3 knock-out mice that also
lacked G-CSF–induced up-regulation of SOCS3.45 Because the
loss of the G-CSF-R C-terminus affects both intensity and duration
of the activation of STATs, we investigated SOCS1 and SOCS3
transcript levels in wild-type and gcsfr-d715 mice, both before and
after 4 days of G-CSF treatment of the mice. G-CSF treatment of
wild-type animals did not affect SOCS1 transcript levels. Receptor
truncation resulted in a modest increase in SOCS1 expression after
G-CSF stimulation, possibly owing to the increased STAT5 activa-
tion by G-CSF-R–d715.31 This is in agreement with data showing
that interleukin 3 (IL-3)–induced SOCS1 expression is almost
completely abrogated in the presence of dominant negative STAT5.89
SOCS3 mRNA levels, on the other hand, increased more than
12-fold in response to G-CSF. SOCS3 levels in gcsfr-d715 mice
were clearly lower than in their wild-type littermates during steady
state and upon stimulation with G-CSF in vivo or in vitro. These
results establish that distinct regulatory mechanisms for up-
regulation of SOCS1 and SOCS3 expression exist in the context of
the G-CSF-R. Recent studies with conditional STAT3 and SOCS3
knock-out strains demonstrated that the levels of neutrophilia in
these mice in response to G-CSF treatment are remarkably similar
to those observed in gcsfr-d715 mice.28,29,45,75,76 This would support
the hypothesis that the loss of the negative feedback loop involving
STAT3-controlled induction of SOCS3 might suffice to explain the
gcsfr-d715 phenotype. However, in view of previous data showing
that STAT3 activation in gcsfr-d715 mice is only moderately and
temporarily reduced,31 it is conceivable that factors other than
STAT3 also contribute to G-CSF–induced SOCS3 expression.
In addition to the reduced expression of SOCS3 in the
gcsfr-d715 mice, the truncated G-CSF-R lacks Tyr729, which is the
major recruitment site for SOCS3.35,36 While this provided an
obvious second mechanism by which the truncated G-CSF-R forms
bypass the suppressive effects of SOCS3, this applied to the
activation of STAT5 but not STAT3, which still remained SOCS3
sensitive (Figure 3). This result provides a likely explanation for
the increased ratio of STAT5/STAT3 activation by G-CSF-R–d715,
which has been linked to shifting the proliferation/differentiation
balance toward proliferation and extended cell survival.31 Two
potential explanations, differential involvement of upstream ty-
rosine kinases and differential sensitivity due to altered internaliza-
tion kinetics, were shown, respectively, to play no or only a limited
role in this study. For efficient activation of STAT3, first G-CSF-R
tyrosine phosphorylation is required, which creates STAT3 recruit-
ment sites. This indicates that activation of STAT3 is a multistep
process. It is conceivable that inhibition of STAT3 is still achieved
when recruitment of SOCS3 is suboptimal owing to the lack of
Tyr729. In contrast, inhibition of STAT5, which is activated
through direct interaction with Jak kinases,90 may require optimal
SOCS3 recruitment for complete inhibition. STAT5 activation by
G-CSF-R mutant Tyr729Phe was inhibited to a considerable extent
at the highest levels of SOCS3, which is probably mediated
through low-affinity interaction of SOCS3 and Jaks.
Moreover, we think that the loss of recruitment of SHP-2
activity to Tyr729 also plays a major role in the sustained STAT5
activation by G-CSF-R–d715. It was shown for a number of
cytokine receptors, for example, the leptin receptor and the shared
cytokine receptor subunit gp130, that SOCS3 and SHP-2 dock to
the same phosphotyrosine-based motif.57-60,91,92 Our data on the
G-CSF-R (Figure 6) corroborate this and implicate Tyr729 as a
common recruitment site for SOCS3 and SHP-2. Because SHP-2
was recently identified as a STAT5 phosphatase, a model can be
envisaged in which impaired recruitment of SHP-2 is key to the
loss of negative control of STAT5 activation.87,88 In this scenario,
reduced recruitment of SHP-2 activity to the G-CSF-R would thus
result in increased levels of active STAT5 complexes. Indeed, as
shown in Figure 6B, G-CSF-R-Tyr729 is essential for formation of
a SHP-2–STAT5 complex, which strongly argues for a scenario in
which loss of Tyr729 not only affects SOCS3-mediated inhibition
of STAT5 activity but also disrupts formation of a SHP-2–STAT5
complex that has been reported to contribute to STAT5
dephosphorylation.
In conclusion, our study has unveiled a new mechanism by
which C-terminal truncation mutants of G-CSF-R, associated with
leukemic progression of SCN, attain altered signaling abilities.
While the altered signaling abilities were originally attributed
mainly to defective internalization properties of G-CSF-R–
d71527,31,86 the loss of negative feedback projected by SOCS3 and,
possibly, SHP-2 via binding to Tyr729 of G-CSF-R have now been
identified as additional signaling defects of truncated G-CSF-R.
Our results fit into a model in which the combined loss of
regulation by SOCS3 and SHP-2 contributes to the perturbed
signaling by G-CSF-R–d715, resulting in an increased STAT5/
STAT3 activation ratio.
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